Literature DB >> 15163495

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

I Stephenson1, J M Wood, K G Nicholson, A Charlett, M C Zambon.   

Abstract

Haemagglutination-inhibition (HI) tests are a simple method used to assess immune responses to influenza haemagglutinin. However, HI tests are insensitive at detection of antibody responses to avian haemagglutinin after vaccination or natural infection, even in the presence of high titres of neutralising antibody or virus isolation. Avian influenza viruses preferentially bind to sialic acid receptors that contain N-acetylneuraminic acid alpha2,3-galactose (alpha2,3Gal) linkages while human viruses preferentially bind to those containing N-acetylneuraminic acid alpha2,6-galactose (alpha2,6Gal) linkages. By using horse erythrocytes in the HI test and thereby increasing the proportion of alpha2,3Gal linkages available for binding, we are able to demonstrate improved detection of antibody to avian H5 in human sera following vaccination with MF59-adjuvanted A/Duck/Singapore/97 surface antigen vaccine. This modified HI test was more sensitive in detection of anti-H5 antibody evoked by revaccination of primed subjects and may be useful in assessing potential avian HA vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163495     DOI: 10.1016/j.virusres.2004.02.019

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  93 in total

1.  Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.

Authors:  Ali H Ellebedy; Christopher Lupfer; Hazem E Ghoneim; Jennifer DeBeauchamp; Thirumala-Devi Kanneganti; Richard J Webby
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

2.  Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Authors:  Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham
Journal:  Contemp Clin Trials       Date:  2015-08-12       Impact factor: 2.226

3.  Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.

Authors:  Wilbur H Chen; Patricia L Winokur; Kathryn M Edwards; Lisa A Jackson; Anna Wald; Emmanuel B Walter; Diana L Noah; Mark Wolff; Karen L Kotloff
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

4.  Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.

Authors:  Wentao Gao; Adam C Soloff; Xiuhua Lu; Angela Montecalvo; Doan C Nguyen; Yumi Matsuoka; Paul D Robbins; David E Swayne; Ruben O Donis; Jacqueline M Katz; Simon M Barratt-Boyes; Andrea Gambotto
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

Authors:  M A Hoelscher; L Jayashankar; S Garg; V Veguilla; X Lu; N Singh; J M Katz; S K Mittal; S Sambhara
Journal:  Clin Pharmacol Ther       Date:  2007-10-24       Impact factor: 6.875

6.  Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.

Authors:  Sanjay Garg; Mary Hoelscher; Jessica A Belser; Chong Wang; Lakshmi Jayashankar; Zhu Guo; Ross H Durland; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

7.  A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

Authors:  Mary A Hoelscher; Neetu Singh; Sanjay Garg; Lakshmi Jayashankar; Vic Veguilla; Aseem Pandey; Yumi Matsuoka; Jacqueline M Katz; Ruben Donis; Suresh K Mittal; Suryaprakash Sambhara
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

8.  Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza viruses.

Authors:  Mariette F Ducatez; Zhipeng Cai; Malik Peiris; Yi Guan; Zhiping Ye; Xiu-Feng Wan; Richard J Webby
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

9.  Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.

Authors:  Neal Van Hoeven; Jessica A Belser; Kristy J Szretter; Hui Zeng; Peter Staeheli; David E Swayne; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

10.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.